Eosinophilic Esophagitis Market Insights 2034: Clinical Research, FDA Approvals, Drugs, Revenue Projections, Market Statistics, Therapies, Prevalence, and Companies by DelveInsight

The Eosinophilic Esophagitis Treatment Market Size in the 7MM was approximately USD 1,800 million in the 2023, which is expected to grow during the forecast period (2020-2034). Key companies active in the Eosinophilic Esophagitis (EoE) market include Ellodi Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Sanofi, Bristol-Myers Squibb, Allakos, EsoCap AG, Pfizer, Ception Therapeutics, Celgene, Dr. Falk Pharma GmbH, Revolo Biotherapeutics, Shire, Novartis, EMS, Oxagen Ltd, Meritage Pharma, Inc., Forest Laboratories, and several others.

(Albany, USA) - DelveInsight's latest report, "Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast - 2034", delivers a comprehensive review of Eosinophilic Esophagitis, providing detailed epidemiology, historical trends, and forward-looking projections. The study covers market dynamics in the United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The analysis explores current treatment standards, the pipeline of emerging therapies, market share by drug class, and forecasted EoE market size from 2020 to 2034 across the seven major markets (7MM). In addition, it outlines the treatment approaches, algorithms, market drivers and barriers, and unmet medical needs while identifying the most promising business opportunities within this therapeutic space.

To explore the detailed market forecast, uptake of therapies, treatment trends, and epidemiology insights, visit: Eosinophilic Esophagitis Market Forecast - https://www.delveinsight.com/report-store/eosinophilic-esophagitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Highlights from the Eosinophilic Esophagitis Market Report:
• In 2023, the EoE treatment market size across the 7MM was approximately USD 1.8 billion, with expectations of steady growth through 2034.
• Sanofi (June 2025): Presented findings from a Phase 4 randomized, placebo-controlled study assessing Dupilumab in adult EoE patients.
• Celldex Therapeutics (May 2025): Announced results from its Phase 2 "EvolvE" trial evaluating Barzolvolimab (CDX-0159).
• AstraZeneca (May 2025): Shared Phase 3 CROSSING study results for Tezepelumab in EoE patients.
• Eupraxia Pharmaceuticals (May & Feb 2025): Disclosed updates on EP-104GI via the RESOLVE Phase 1b/2a trial and hosted a KOL event on advancements in EoE treatment.
• Holoclara (Dec 2024): Initiated Phase 1 trials of HC002, targeting worm-derived therapies for EoE and other autoimmune disorders.
• Apogee Therapeutics (Dec 2024): Began first-in-human dosing of APG333, a novel monoclonal antibody targeting TSLP, initially for asthma, COPD, and EoE.
• Regeneron & Sanofi (Sept 2024): Received positive CHMP opinion recommending expanded approval of DUPIXENT (dupilumab) for children aged 1-11 years with EoE.
• Takeda (Feb 2024): Secured FDA approval for EOHILIA (budesonide oral suspension), the first oral therapy for EoE patients 11 years and older.
• FDA (Jan 2024): Approved DUPIXENT for pediatric EoE patients (1-11 years, ≥15 kg), based on positive Phase III EoE KIDS trial results.
• Currently, only a limited number of drugs are approved for EoE, including DUPIXENT (dupilumab) and JORVEZA (budesonide).
• In 2023, diagnosed prevalent cases of EoE across the 7MM reached ~800,000, projected to grow at a moderate CAGR by 2034.
• The United States accounted for nearly 500,000 cases, representing the highest share among the 7MM.
• Within the EU4 and UK, Germany reported the largest number of cases, with France following closely.
• According to NORD, approximately 1 in 2,000 people are affected by EoE.
• Historical data suggests the U.S. reported 319,429 cases in 2020, marking it as the highest prevalence region.
• Prominent Companies in the EoE Market: Regeneron, Sanofi, Bristol-Myers Squibb, Ellodi, AstraZeneca, Allakos, EsoCap AG, Pfizer, Ception, Celgene, Dr. Falk Pharma, Revolo, Shire, Novartis, EMS, Oxagen, Meritage Pharma, Forest Laboratories, and others.
• Key Therapies Under Development or in Use: Dupilumab, Cendakimab, APT-1011, Benralizumab, Lirentelimab, ESO-101, Etrasimod, Reslizumab, CC-93538, Mesalamine, IRL201104, Budesonide, QAX576, Florence, RPC4046, OC000459, Budesonide + Prevacid, EUR-1100, among others.
• Epidemiological studies show that EoE affects more males than females. Market expansion is anticipated due to the growing prevalence and heightened awareness of the disease, alongside the launch of late-stage pipeline therapies expected to significantly transform treatment dynamics.

Eosinophilic Esophagitis (EoE) - Overview
EoE is a chronic, immune-driven inflammatory disorder of the esophagus, marked by eosinophil infiltration of esophageal tissues. Typically triggered by food allergens or environmental exposures, it manifests as dysphagia (difficulty swallowing), food impaction, chest pain, and heartburn unresponsive to PPIs.
Diagnosis relies on endoscopy and biopsy, where tissue samples confirm eosinophil presence. Adults often report dysphagia and impaction, while children may present with vomiting, feeding problems, or failure to thrive.
Treatment strategies involve dietary interventions (elimination or elemental diets), proton pump inhibitors, topical corticosteroids, and in severe cases, esophageal dilation. Ongoing research is driving the development of targeted biologics and novel therapies aimed at improving outcomes and quality of life.

Request a free sample of the EoE Market Report here: DelveInsight - Eosinophilic Esophagitis Market Report - https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Epidemiology Insights (2020-2034)
The Eosinophilic Esophagitis epidemiology section covers historical and forecasted trends (2020-2034) across the 7MM (US, EU4, UK, Japan), segmented by total diagnosed prevalence, gender, age, and treated cases. In 2023, the US recorded the highest diagnosed prevalence with ~445,000 cases, projected to rise further. The disease showed a male predominance (290,000 males vs. 156,000 females), and adults over 18 years were the most affected, with about 156,000 cases.

Drug Uptake and Pipeline Developments
The drug uptake section analyzes launch timelines, patient adoption, and sales trajectory of recently approved and upcoming therapies. Comparative assessments reveal the fastest-growing therapies and their market impact.

Key Pipeline Therapies: Dupilumab (Regeneron/Sanofi), Cendakimab (BMS), APT-1011 (Ellodi), Benralizumab (AstraZeneca), Lirentelimab (Allakos), ESO-101 (EsoCap), Etrasimod (Pfizer), Reslizumab (Ception), CC-93538 (Celgene), Mesalamine (Dr. Falk), IRL201104 (Revolo), Budesonide (Shire), QAX576 (Novartis), Florence (EMS), RPC4046 (Celgene), OC000459 (Oxagen), Budesonide + Prevacid (Meritage), EUR-1100 (Forest).

Discover pipeline therapies expected to dominate the market: EoE Treatment Market - https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Report
• Study Period: 2020-2034
• Regions Covered: United States, EU5 (Germany, France, Italy, Spain, UK), and Japan
• Companies: Regeneron, Sanofi, BMS, AstraZeneca, Allakos, Pfizer, Celgene, Dr. Falk Pharma, Revolo, Shire, Novartis, EMS, Oxagen, Meritage, Forest, Ellodi, and others
• Therapies: Dupilumab, Cendakimab, APT-1011, Benralizumab, Lirentelimab, ESO-101, Etrasimod, Reslizumab, CC-93538, Mesalamine, IRL201104, Budesonide, QAX576, Florence, RPC4046, OC000459, Budesonide + Prevacid, EUR-1100, and more
• Analysis Includes: SWOT, PESTLE, Porter's Five Forces, BCG Matrix, reimbursement insights, market access, analyst and KOL viewpoints

For more details on trial activity, FDA/EMA approvals, and company involvement, visit: Eosinophilic Esophagitis Clinical Trials & Approvals - https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.